Publications
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R, Maksimovic N, Stroggilos R, Zoidakis J, Castellví-Bel S, Fijneman RJA, and Cavic M. Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front. Genet. 2023, 14:1245594. doi: 10.3389/fgene.2023.1245594. link: https://www.frontiersin.org/
2023 Marinkovic et al.
2023 Marinkovic et al.
Stanojevic A, Samiotaki M, Lygirou V, Marinkovic M, Nikolic V, Stojanovic-Rundic S, Jankovic R, Vlahou A, Panayotou G, Fijneman RJA, Castellví-Bel S, Zoidakis J, and Cavic M. Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy. International Journal of Molecular Sciences. 2023; 24(20):15412. https://doi.org/10.3390/
https://www.mdpi.com/1422-
https://www.mdpi.com/1422-
Vuletić A, Mirjačić Martinović K, Spasić J. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. Pharmaceutics. 2024; 16(1):54. https://doi.org/10.3390/
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Tomasevic A, Jankovic R, Zoidakis J, Castellví-Bel S, Fijneman RJA, Cavic M, Radulovic M. Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction. Journal of Clinical Medicine. 2024; 13(2):421. https://doi.org/10.3390/
Stanojevic A, Spasic J, Marinkovic M, Stojanovic-Sundic S, Jankovic R, Djuric A, Zoidakis J, Fijneman RJA, Castellvi-Bel S, Cavic M. Methylenetetrahydrofolate reductase polymorphic variants C677T and A1298C in rectal cancer in Slavic population: significance for cancer risk and response to chemoradiotherapy. Frontiers in Genetics. 2023; 14. https://doi.org/10.3389/
Cavic M, Nikolic N, Marinkovic M, Damjanovic A, Krivokuca A, Tanic M, Radulovic M, Stanojevic A, Pejnovic L, Djordjic Crnogorac M, Djuric A, Vukovic M, Stevanovic V, Kijac J, Karadzic V, Nikolic S, Stojanovic-Rundic S, Jankovic R, Spasic J. Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia—Insights from the Institute for Oncology and Radiology of Serbia. Biomedicines. 2024; 12(10):2278. https://doi.org/10.3390/
https://www.mdpi.com/2227-
https://www.mdpi.com/2227-
Stojanovic-Rundic S, Marinkovic M, Stanojevic A, Gavrilovic D, Jankovic R, Maksimovic N, Tomasevic A, Petrasinovic P, Radenkovic S, Cavic M. Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Short-Term Efficacy and Toxicity of VMAT–SIB vs. 3D-CRT. Medicina. 2025; 61(3):483. https://doi.org/10.3390/
Herrera-Pariente C, Bonjoch L, Muñoz J, Fernàndez G, Soares de Lima Y, Mahmood R, Cuatrecasas M, Ocaña T, Lopez-Prades S, Llargués-Sistac G, Domínguez-Rovira X, Llach J, Luzko I, Díaz-Gay M, Lazaro C, Brunet J, Castillo-Manzano C, García-González MA, Lanas A, Carrillo M, Hernández San Gil R, Quintero E, Sala N, Llort G, Aguilera L, Carot L, Diez-Redondo P, Jover R, Ramon Y Cajal T, Cubiella J, Castells A, Balaguer F, Bujanda L, Castellví-Bel S, Moreira L. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions. Gastric Cancer. 2024 Jul;27(4):747-759. doi: 10.1007/s10120-024-01504-7.
https://link.springer.com/article/10.1007/s10120-024-01504-7
https://link.springer.com/article/10.1007/s10120-024-01504-7
Damjanovic A, Tanic M, Nedeljkovic M, Jankovic R. CtDNA: What We Know and What We Are Looking For. Oncology Insights. 2024, 2:9-15. https://plus.cobiss.net/
Cavic M, Djuric A, Marinkovic M, Stanojevic A, Tanic M, Bjelogrlic S, Spasic J, Damjanovic A, Djordjic Crnogorac M, Vuletic A, Mirjacic Martinovic K, Radulovic M, Stojanovic-Rundic S, Krivokuca A, Jankovic R, Castellvi-Bel S, Zoidakis J, Fijneman R. Employing widening funds to address inequity in cancer research – example of the STEPUPIORS collaborative rectal cancer project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1304. https://doi.org/10.1158/1538-
Stanojevic A, Stroggilos R, Marinkovic M, Stojanovic-Rundic S, Jankovic R, Castellvi-Bel S, Fijneman R, Vlahou A, Zoidakis J, Cavic M. Meta-analysis of publicly available transcriptomics data reveals predictive biomarkers for neoadjuvant chemoradiotherapy in rectal cancer. Radiotherapy and Oncology, Volume 206 (Suppl. 1): 4024-4025. ESTRO 2025: Transformative Innovation through Partnership, 02-06 May 2025, Vienna, Austria. Abstract No. 4395. https://www.sciencedirect.com/science/article/abs/pii/S016781402503350X →
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R, Maksimovic N, Stroggilos R, Zoidakis J, Castellvi-Bel S, Fijneman R.J.A, Cavic M. Exploring novel inflammation-related genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. medRxiv 2023.06.20.23291673; doi: https://doi.org/10.1101/2023.
Vuletić, A., Mirjačić Martinović, K., & Spasić, J. (2023). Role of HDAC6 and HDAC6 Inhibition in Colorectal Cancer. Preprints.
https://doi.org/10.20944/
https://doi.org/10.20944/
Cavic M, Nikolic N, Marinkovic M, Damjanovic A, Krivokuca A, Tanic M, Radulovic M, Stanojevic A, Pejnovic L, Djordjic Crnogorac M, Djuric A, Vukovic M, Stevanovic V, Kijac J, Karadzic V, Nikolic S, Stojanovic-Rundic S, Jankovic R, Spasic J. Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia – Insights from the Institute for Oncology and Radiology of Serbia. Preprints, 2024, 2024090672. doi: 10.20944/preprints202409.0672.
https://www.preprints.org/
https://www.preprints.org/
Stojanovic-Rundic, S., Marinkovic, M., Stanojevic, A., Gavrilovic, D., Jankovic, R., Maksimovic, N., Tomasevic, A., Petrasinovic, P., Radenkovic, S., & Cavic, M. (2025). Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Efficacy and Toxicity of VMAT-SIB vs. 3D-CRT. Preprints. https://doi.org/10.20944/
Stanojevic A, Stroggilos R, Marinkovic M, Djuric A, Stojanovic-Rundic S, Jankovic R, Castellvi-Bel S, Fijneman R, Vlahou A, Zoidakis J, Cavic M. Profiling Neoadjuvant Therapy Response in Rectal Cancer Using Publicly Available Transcriptomic RNA-seq Datasets. medRxiv 2025.07.18.25331799; doi: https://doi.org/10.1101/2025.
Proteomics Dataset
Stanojevic A, Samiotaki M, Lygirou V, Marinkovic M, Nikolic V, Stojanovic-Rundic S, Jankovic R, Vlahou A, Panayotou G, Fijneman RJA, Castellví-Bel S, Zoidakis J, Cavic M. Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy. Int J Mol Sci. 2023 24(20):1541. DOI: 10.3390/ijms242015412, PubMed: 37895091.
Accessible at: http://www.ebi.ac.uk/pride/
Radiomics Dataset
Marko Radulovic, Mladen Marinkovic, & Milena Cavic. (2023). MRI Radiomics data of LARC patients who responded well and poorly to nCRT-Manuscript: Performance and Dimensionality of Pretreatment MRI Radiomics in Prediction of Rectal Carcinoma Response to Chemoradiotherapy. https://doi.org/10.5281/
Accessible at: https://zenodo.org/records/
Mladen Marinković. Evaluation of Prognostic and Predictive Clinical and Molecular Markers in Locally Advanced Rectal Cancer Patients treated with Neoadjuvant Radiochemotherapy using Volumetric Modulated Arc Therapy Planning and Simultaneous Integrated Boost. Faculty of Medicine, University of Belgrade, Serbia. Thesis defended on 08.07.2024.
https://uvidok.rcub.bg.ac.rs/
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R, Maksimovic N, Stroggilos R, Zoidakis J, Castellví-Bel S, Fijneman RJA, and Cavic M. Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front. Genet. 2023, 14:1245594. doi: 10.3389/fgene.2023.1245594. link: https://www.frontiersin.org/
2023 Marinkovic et al.
2023 Marinkovic et al.
Stanojevic A, Samiotaki M, Lygirou V, Marinkovic M, Nikolic V, Stojanovic-Rundic S, Jankovic R, Vlahou A, Panayotou G, Fijneman RJA, Castellví-Bel S, Zoidakis J, and Cavic M. Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy. International Journal of Molecular Sciences. 2023; 24(20):15412. https://doi.org/10.3390/
https://www.mdpi.com/1422-
https://www.mdpi.com/1422-
Vuletić A, Mirjačić Martinović K, Spasić J. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. Pharmaceutics. 2024; 16(1):54. https://doi.org/10.3390/
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Tomasevic A, Jankovic R, Zoidakis J, Castellví-Bel S, Fijneman RJA, Cavic M, Radulovic M. Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction. Journal of Clinical Medicine. 2024; 13(2):421. https://doi.org/10.3390/
Stanojevic A, Spasic J, Marinkovic M, Stojanovic-Sundic S, Jankovic R, Djuric A, Zoidakis J, Fijneman RJA, Castellvi-Bel S, Cavic M. Methylenetetrahydrofolate reductase polymorphic variants C677T and A1298C in rectal cancer in Slavic population: significance for cancer risk and response to chemoradiotherapy. Frontiers in Genetics. 2023; 14. https://doi.org/10.3389/
Cavic M, Nikolic N, Marinkovic M, Damjanovic A, Krivokuca A, Tanic M, Radulovic M, Stanojevic A, Pejnovic L, Djordjic Crnogorac M, Djuric A, Vukovic M, Stevanovic V, Kijac J, Karadzic V, Nikolic S, Stojanovic-Rundic S, Jankovic R, Spasic J. Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia—Insights from the Institute for Oncology and Radiology of Serbia. Biomedicines. 2024; 12(10):2278. https://doi.org/10.3390/
https://www.mdpi.com/2227-
https://www.mdpi.com/2227-
Stojanovic-Rundic S, Marinkovic M, Stanojevic A, Gavrilovic D, Jankovic R, Maksimovic N, Tomasevic A, Petrasinovic P, Radenkovic S, Cavic M. Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Short-Term Efficacy and Toxicity of VMAT–SIB vs. 3D-CRT. Medicina. 2025; 61(3):483. https://doi.org/10.3390/
Herrera-Pariente C, Bonjoch L, Muñoz J, Fernàndez G, Soares de Lima Y, Mahmood R, Cuatrecasas M, Ocaña T, Lopez-Prades S, Llargués-Sistac G, Domínguez-Rovira X, Llach J, Luzko I, Díaz-Gay M, Lazaro C, Brunet J, Castillo-Manzano C, García-González MA, Lanas A, Carrillo M, Hernández San Gil R, Quintero E, Sala N, Llort G, Aguilera L, Carot L, Diez-Redondo P, Jover R, Ramon Y Cajal T, Cubiella J, Castells A, Balaguer F, Bujanda L, Castellví-Bel S, Moreira L. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions. Gastric Cancer. 2024 Jul;27(4):747-759. doi: 10.1007/s10120-024-01504-7.
https://link.springer.com/article/10.1007/s10120-024-01504-7
https://link.springer.com/article/10.1007/s10120-024-01504-7
Damjanovic A, Tanic M, Nedeljkovic M, Jankovic R. CtDNA: What We Know and What We Are Looking For. Oncology Insights. 2024, 2:9-15. https://plus.cobiss.net/
Cavic M, Djuric A, Marinkovic M, Stanojevic A, Tanic M, Bjelogrlic S, Spasic J, Damjanovic A, Djordjic Crnogorac M, Vuletic A, Mirjacic Martinovic K, Radulovic M, Stojanovic-Rundic S, Krivokuca A, Jankovic R, Castellvi-Bel S, Zoidakis J, Fijneman R. Employing widening funds to address inequity in cancer research – example of the STEPUPIORS collaborative rectal cancer project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1304. https://doi.org/10.1158/1538-
Stanojevic A, Stroggilos R, Marinkovic M, Stojanovic-Rundic S, Jankovic R, Castellvi-Bel S, Fijneman R, Vlahou A, Zoidakis J, Cavic M. Meta-analysis of publicly available transcriptomics data reveals predictive biomarkers for neoadjuvant chemoradiotherapy in rectal cancer. Radiotherapy and Oncology, Volume 206 (Suppl. 1): 4024-4025. ESTRO 2025: Transformative Innovation through Partnership, 02-06 May 2025, Vienna, Austria. Abstract No. 4395. https://www.sciencedirect.com/science/article/abs/pii/S016781402503350X →
Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R, Maksimovic N, Stroggilos R, Zoidakis J, Castellvi-Bel S, Fijneman R.J.A, Cavic M. Exploring novel inflammation-related genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. medRxiv 2023.06.20.23291673; doi: https://doi.org/10.1101/2023.
Vuletić, A., Mirjačić Martinović, K., & Spasić, J. (2023). Role of HDAC6 and HDAC6 Inhibition in Colorectal Cancer. Preprints.
https://doi.org/10.20944/
https://doi.org/10.20944/
Cavic M, Nikolic N, Marinkovic M, Damjanovic A, Krivokuca A, Tanic M, Radulovic M, Stanojevic A, Pejnovic L, Djordjic Crnogorac M, Djuric A, Vukovic M, Stevanovic V, Kijac J, Karadzic V, Nikolic S, Stojanovic-Rundic S, Jankovic R, Spasic J. Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia – Insights from the Institute for Oncology and Radiology of Serbia. Preprints, 2024, 2024090672. doi: 10.20944/preprints202409.0672.
https://www.preprints.org/
https://www.preprints.org/
Stojanovic-Rundic, S., Marinkovic, M., Stanojevic, A., Gavrilovic, D., Jankovic, R., Maksimovic, N., Tomasevic, A., Petrasinovic, P., Radenkovic, S., & Cavic, M. (2025). Dose Escalation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Efficacy and Toxicity of VMAT-SIB vs. 3D-CRT. Preprints. https://doi.org/10.20944/
Stanojevic A, Stroggilos R, Marinkovic M, Djuric A, Stojanovic-Rundic S, Jankovic R, Castellvi-Bel S, Fijneman R, Vlahou A, Zoidakis J, Cavic M. Profiling Neoadjuvant Therapy Response in Rectal Cancer Using Publicly Available Transcriptomic RNA-seq Datasets. medRxiv 2025.07.18.25331799; doi: https://doi.org/10.1101/2025.
Proteomics Dataset
Stanojevic A, Samiotaki M, Lygirou V, Marinkovic M, Nikolic V, Stojanovic-Rundic S, Jankovic R, Vlahou A, Panayotou G, Fijneman RJA, Castellví-Bel S, Zoidakis J, Cavic M. Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy. Int J Mol Sci. 2023 24(20):1541. DOI: 10.3390/ijms242015412, PubMed: 37895091.
Accessible at: http://www.ebi.ac.uk/pride/
Radiomics Dataset
Marko Radulovic, Mladen Marinkovic, & Milena Cavic. (2023). MRI Radiomics data of LARC patients who responded well and poorly to nCRT-Manuscript: Performance and Dimensionality of Pretreatment MRI Radiomics in Prediction of Rectal Carcinoma Response to Chemoradiotherapy. https://doi.org/10.5281/
Accessible at: https://zenodo.org/records/
Mladen Marinković. Evaluation of Prognostic and Predictive Clinical and Molecular Markers in Locally Advanced Rectal Cancer Patients treated with Neoadjuvant Radiochemotherapy using Volumetric Modulated Arc Therapy Planning and Simultaneous Integrated Boost. Faculty of Medicine, University of Belgrade, Serbia. Thesis defended on 08.07.2024.
https://uvidok.rcub.bg.ac.rs/
